MedPath

Tikosyn

TIKOSYN (dofetilide) Capsules

Approved
Approval ID

b77b4388-36ec-4971-90a5-353879adb8b5

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 24, 2017

Manufacturers
FDA

Avera McKennan Hospital

DUNS: 068647668

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

dofetilide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69189-5820
Application NumberNDA020931
Product Classification
M
Marketing Category
C73594
G
Generic Name
dofetilide
Product Specifications
Route of AdministrationORAL
Effective DateMarch 24, 2017
FDA Product Classification

INGREDIENTS (5)

DOFETILIDEActive
Quantity: 0.5 mg in 1 1
Code: R4Z9X1N2ND
Classification: ACTIB
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT

Drug Labeling Information

BOXED WARNING SECTION

LOINC: 34066-1Updated: 10/12/2016

Drug/Laboratory Test Interactions

None known.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tikosyn - FDA Drug Approval Details